Objective This study intended to establish a droplet digital PCR (dd‐PCR) for monitoring
minimal residual disease (MRD) in patients with BCR/ABL (P210)‐positive chronic myeloid …

Simple Summary The introduction to clinical practice of a treatment-free remission approach
in chronic myeloid leukemia patients with a stable deep molecular response highlighted …

Real-time quantitative PCR (qPCR) is routinely used to detect minimal residual disease in
chronic myeloid leukemia patients. The absolute quantification with droplet digital PCR …

BCR-ABL1 fusion transcript is the minimal residual disease marker in chronic myeloid
leukemia; 2% of patients show unusual breakpoints generating atypical transcripts, not …

Recent studies indicate that 40% of chronic myeloid leukemia patients who achieve
sustained undetectable BCR-ABL1 transcripts on tyrosine kinase inhibitor therapy remain …

Measurement of BCR activator of RhoGEF and GTPase‐ABL proto‐oncogene 1, non‐
receptor tyrosine kinase (BCR‐ABL1) mRNA levels by reverse transcription quantitative …

Quantitative real-time PCR methods are commonly used to monitor BCR-ABL transcript
levels in patients with chronic myelogenous leukemia. However, standard techniques …

Philadelphia-positive (Ph+), BCR-ABL1, chronic myeloid leukemia (CML) is a model of
leukemia driven by a single, specific, chromosome translocation, the t (9; 22)(q22; q11). This …

Formed from a reciprocal translocation t (9: 22)(q34; q11) of genetic material between the
long arms of human chromosomes 9 and 22, the constitutively active breakpoint cluster …

Accurate detection of BCR-ABL fusion transcripts at and below molecular response (MR) 4
(0.01% International Scale [IS]) is required for disease monitoring in patients with chronic …